Sign in

    Kalpit Patel • B. Riley Securities

    Kalpit Patel's questions to Syndax Pharmaceuticals Inc (SNDX) leadership

    Kalpit Patel's questions to Syndax Pharmaceuticals Inc (SNDX) leadership • Q1 2025

    Question

    Kalpit Patel from B. Riley Securities asked for a breakdown of Q1 Revuforj revenue between new patient starts and refills, and for an early estimate of the median duration of therapy.

    Answer

    Chief Commercial Officer Steven Closter responded that it is too early to provide a specific breakdown, as the data is still maturing, but confirmed that both new starts and refills are building strongly, with some patients on their fifth refill. He stated that a definitive median duration of therapy will take a couple more quarters to establish, but early compliance data is encouraging.

    Ask Fintool Equity Research AI

    Kalpit Patel's questions to Syndax Pharmaceuticals Inc (SNDX) leadership • Q3 2024

    Question

    Kalpit Patel of B. Riley Securities asked if there's a minimum efficacy threshold for KMT2A patients to be included on the frontline label and what additional analyses for the pivotal KMT2A cohort might be presented at ASH.

    Answer

    Dr. Neil Gallagher, President and Head of R&D, explained the frontline trial is powered for NPM1, and while they will look for consistency in KMT2A patients, the study is not designed to test a statistical hypothesis for that group. He also indicated that more detailed analyses of the KMT2A data would be presented at ASH but did not specify the details.

    Ask Fintool Equity Research AI

    Kalpit Patel's questions to Kymera Therapeutics Inc (KYMR) leadership

    Kalpit Patel's questions to Kymera Therapeutics Inc (KYMR) leadership • Q3 2024

    Question

    Kalpit Patel from B. Riley Securities inquired about preclinical comparisons of KT-621 to dupilumab in atopic dermatitis models, specifically regarding ear thickness, and asked about the projected human equivalent dose based on mouse model data.

    Answer

    CEO Nello Mainolfi clarified that Kymera focuses on Th2 biomarkers and asthma models over ear thickness, which is a less specific measure. He advised that dose projections should be based on dog and monkey data, not mouse data, due to protein binding differences, suggesting the human dose range will be broadly similar to the IRAK4 program.

    Ask Fintool Equity Research AI

    Kalpit Patel's questions to Kymera Therapeutics Inc (KYMR) leadership • Q1 2024

    Question

    Kalpit Patel asked about the degradation kinetics for the STAT6 program, referencing a previous protein rebound observed with the IRAK4 program, and questioned what steps are being taken to ensure accurate measurement of target knockdown.

    Answer

    President and CEO Nello Mainolfi clarified that the IRAK4 issue was specific to using flow cytometry in a multi-site patient study, where sample handling can introduce variability, unlike the more robust mass spectrometry used in healthy volunteer trials. He assured that for the KT-621 studies, they have planned for multiple opportunities and methods to ensure accurate protein level measurements.

    Ask Fintool Equity Research AI